NO20035771L - Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger - Google Patents

Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger

Info

Publication number
NO20035771L
NO20035771L NO20035771A NO20035771A NO20035771L NO 20035771 L NO20035771 L NO 20035771L NO 20035771 A NO20035771 A NO 20035771A NO 20035771 A NO20035771 A NO 20035771A NO 20035771 L NO20035771 L NO 20035771L
Authority
NO
Norway
Prior art keywords
assays
epf
well
test compound
therapeutic compositions
Prior art date
Application number
NO20035771A
Other languages
English (en)
Other versions
NO341778B1 (no
Inventor
Eckhard Bender
Arjan Buist
Tom Julia Leon Meeusen
Elke Jenny Henriette Clynen
Liliane Amelie Henrica Shoofs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20035771L publication Critical patent/NO20035771L/no
Publication of NO341778B1 publication Critical patent/NO341778B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

Det tilveiebringes assayer for å undersøke vekselvirkningen mellom EPF og EPF-beslektede peptider med en hDRR-receptor. Assayene er nyttige for å identifisere om en testforbindelse kan bindes til hDRR-receptor under betingelser hvor EPF eller beslektede peptider kan bindes til receptoren. Assayene er også nyttige for å bestemme om testforbindelsen er en agonist eller antagonist av hDRR'er. De ovennevnte assayer kan utføres i forskjellige formater, bl.a. kompetitive, ikke-kompetitive og sammenlignende assayer, hvor vekselvirkningen mellom EPF eller EPF-beslektede peptider og hDRR'er bedømmes som positiv- eller negativ-kontroll eller sammenlignes med resultatene som ble erholdt med testforbindelsen.
NO20035771A 2001-06-27 2003-12-22 Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger NO341778B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202474 2001-06-27
PCT/EP2002/007263 WO2003005036A2 (en) 2001-06-27 2002-06-26 Epf receptor assays, compounds and therapeutic compositions

Publications (2)

Publication Number Publication Date
NO20035771L true NO20035771L (no) 2004-02-26
NO341778B1 NO341778B1 (no) 2018-01-15

Family

ID=8180549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035771A NO341778B1 (no) 2001-06-27 2003-12-22 Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger

Country Status (17)

Country Link
US (2) US20040235722A1 (no)
EP (1) EP1399744B1 (no)
JP (1) JP4326326B2 (no)
KR (2) KR100971270B1 (no)
CN (1) CN100406891C (no)
AT (1) ATE397218T1 (no)
AU (1) AU2002317013B2 (no)
CA (1) CA2450502C (no)
DE (1) DE60226867D1 (no)
DK (1) DK1399744T3 (no)
ES (1) ES2307767T3 (no)
HK (1) HK1070694A1 (no)
IL (2) IL158817A0 (no)
NO (1) NO341778B1 (no)
NZ (1) NZ529714A (no)
WO (1) WO2003005036A2 (no)
ZA (1) ZA200309823B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340979A3 (en) * 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
ATE520028T1 (de) 2003-06-20 2011-08-15 Discoverx Corp Test zum nachweis von proteinbindung
NZ566817A (en) 2005-08-31 2012-02-24 Cbio Ltd Modified chaperonin 10, wherein the N-terminus comprises a single additional glycine residue compared to a corresponding mammalian wild-type
CN101514335B (zh) 2008-02-22 2013-04-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
WO2009124353A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
WO1999039208A1 (en) * 1998-02-02 1999-08-05 Concepto Diagnostics, Inc. Method and apparatus for detecting conception in animals
CN1379816A (zh) * 1999-09-16 2002-11-13 索尔瓦药物有限公司 人g－蛋白偶联受体
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
IL158817A0 (en) 2004-05-12
HK1070694A1 (en) 2005-06-24
IL158817A (en) 2012-01-31
ATE397218T1 (de) 2008-06-15
KR100971270B1 (ko) 2010-07-20
WO2003005036A2 (en) 2003-01-16
US20040235722A1 (en) 2004-11-25
KR20090111346A (ko) 2009-10-26
EP1399744A2 (en) 2004-03-24
CN1541335A (zh) 2004-10-27
ES2307767T3 (es) 2008-12-01
US20060160145A1 (en) 2006-07-20
AU2002317013B2 (en) 2007-11-01
NZ529714A (en) 2008-04-30
CA2450502A1 (en) 2003-01-16
JP2005503543A (ja) 2005-02-03
ZA200309823B (en) 2005-05-25
KR100977824B1 (ko) 2010-08-25
DK1399744T3 (da) 2008-09-22
KR20040010644A (ko) 2004-01-31
JP4326326B2 (ja) 2009-09-02
WO2003005036A3 (en) 2003-10-16
CN100406891C (zh) 2008-07-30
DE60226867D1 (de) 2008-07-10
EP1399744B1 (en) 2008-05-28
US7402563B2 (en) 2008-07-22
CA2450502C (en) 2017-10-31
NO341778B1 (no) 2018-01-15

Similar Documents

Publication Publication Date Title
Auger et al. Influence of HLA–DR genes on the production of rheumatoid arthritis–specific autoantibodies to citrullinated fibrinogen
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
EA200501724A1 (ru) Соединения, специфичные к меланокортиновым рецепторам
MA29369B1 (fr) Dosage fixe d'anticorps anti-her
CA2358938A1 (en) Methods for assessing, improving, or maintaining urogenital health in postmenopausal women
BR0110079A (pt) Combinação de compostos orgânicos
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
WO2005103713A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
DE602005015135D1 (de) Biologischer marker für entzündung
Wu et al. Functional proteomics approaches for the identification of transnitrosylase and denitrosylase targets
HK1070694A1 (en) Identification of a compound capable of binding to hdrr or capable of modulating hdrr activity using a epf receptor, and isolation of hdrr
CA2279881A1 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
DE60235011D1 (de) Assays für den präimplantationsfaktor und präimplantationsfaktorpeptide
DK2005190T4 (da) Inhibering af GASC1
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
DE69432422D1 (de) Methoden zum aufspüren von anti-östrogenverbindungen
DE69940923D1 (de) Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren
ATE502300T1 (de) Immunoassay-verfahren
WO2003101176A8 (en) Method, composition and kit for antigenic binding of norwalk-like viruses
WO2006023211A3 (en) Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof
ATE408144T1 (de) Assays
DE602005025041D1 (de) Test und kits dafür

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees